- Entheon Biomedical Corp. (ENBI) Launches HaluGen’s Psychedelics Genetic Test
- HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy
- By obtaining DNA test results, individuals and healthcare professionals are equipped with data to improve psychedelic-assisted therapy
- Expected to be available for purchase in the US market within the coming months
- Entheon Biomedical Corp. (ENBI) is down 1.43 per cent and is trading at C$0.69 at 12:01 pm ET
Entheon Biomedical Corp. (ENBI) launches the industry’s first Psychedelics Genetic Test Kit, developed by a wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), and that it is now available for sale within Canada.
HaluGen’s psychedelic pre-screening platform and DNA testing provide genetic, personal, and familial insights to better inform one’s psychedelic-assisted therapy experience.
By obtaining DNA test results, individuals and healthcare professionals are equipped with data to improve psychedelic-assisted therapy patient care and reduce side effects and risk.
The first of its kind, the proprietary test kit and platform, are also expected to be available for purchase in the US market within the coming months.
Entheon is currently pursuing various strategic partnerships to build brand awareness.
HaluGen’s genetic-based testing platform was developed and tested in partnership with Lobo Genetics Inc. (“Lobo”), a Toronto-based healthcare technology company that has successfully commercialized a THC CBD Genetic Test.
Based on a Product Supply and Testing Services Agreement between Lobo and HaluGen, Lobo completed the requirements for commercializing the Psychedelic Pre-Screening Genetic Test.
This includes completing the Assay Development and Technology Platform, the creation of operating procedures and the deployment and successful testing of the technology platform.
The Psychedelics Genetic Test leverages Polymerase Chain Reaction (PCR) technology, a well-established method for genotyping and analyzing DNA. Customers receive a swab kit shipped directly to their home, which they can then register on HaluGen’s secure online portal.
After a non-invasive cheek swab sample is taken, the kit is returned to be processed at HaluGen’s Toronto-based testing facility.
A personalized genetic profile with five individualized sensitivity and risk reports is sent directly to the customer. They are also given access to pre-screening mental health surveys and relevant peer-reviewed scientific studies.
Genetics can play an important role in how an individual responds to psychedelic-assisted psychotherapy.
For example, the HTR2A gene mutation, carried by ~20 percent of the population, can impact how a person responds to serotonin, which is the primary mechanism of serotonergic psychedelics psilocybin, LSD and DMT.
Another gene, CYP2B6, can influence the metabolism of ketamine for the 10-20 per cent of people that carry a specific CYP2B6 gene variant.
HaluGen’s Psychedelics Genetic Test provides users with personalized reports and actionable insights, delivered directly to one’s smartphone, providing a convenient and safe means to better understand an individual’s sensitivity to classical psychedelics and ketamine.
The test also provides insights into the short and long-term potential of psychedelic-induced risks, such as psychosis.
“For patients considering psychedelic-assisted psychotherapy, and providers alike, this product gives greater insight into how an individual’s genetic profile could impact treatment, ultimately improving outcomes,” said Chief Executive Officer Timothy Ko.
Entheon Biomedical Corp. (ENBI) is down 1.43 per cent and is trading at C$0.69 at 12:01 pm ET.
